Proposed medicines(s) for treatment of Early Stage Cervical Cancer (refer to application for specific protocols):

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Currently on EML</th>
<th>Addition</th>
</tr>
</thead>
<tbody>
<tr>
<td>cisplatin</td>
<td>☐</td>
<td>☑</td>
</tr>
</tbody>
</table>

(1) Does the application adequately address the issue of the public health need for the treatment of the disease?

√ Yes ☐ No ☐

Comments: The application adequately address the issue of the public health need for the treatment of the disease as the evidence supports the claim of additional benefit from adjuvant chemotherapy for cervical cancer.

(2) Have all important studies that you are aware of been included in the application?

√ Yes ☐ No ☐

Comments:

(3) Does the application provide adequate evidence of efficacy/effectiveness of the proposed treatment regimen(s)?

√ Yes ☐ No ☐

Comments: The study of Peters and colleagues(2000) reveals that, compared to patients treated with RT and chemotherapy, patients treated with RT alone were found to have lower progression free survival at four years (63 vs. 80%), lower overall survival at four years (71 vs. 81%), and decreased grade 3 or 4 toxicity.

(4) Does the application provide adequate evidence of safety for the proposed treatment regimen(s)? Are there any adverse effects of concern, or that may require special monitoring?

√ Yes ☐ No ☐
Comments: As above.

ADDITIONAL CONSIDERATIONS:

(5) Are there special requirements or training needed for the safe, effective and/or appropriate use of the proposed treatment(s)?

  √ Yes ☐ No ☐

  Comments: Medical Oncologists only can prescribe and supervise chemotherapy for cervical cancer. Chemotherapy–trained nurses only can administer the drugs.

(6) Are there any issues regarding the registration of the proposed medicines by regulatory authorities? (e.g., recent registration, new indications, off-label use)

  Yes ☐ No ☐

  Comments: Not that we are aware.

(7) Comment briefly on issues regarding cost and affordability of treatment.

  Cisplatin is off patent use and widely used in treatment of various malignancies. Therefore, the cost and affordability of treatment should not pose any additional significant burden on the health systems of different countries.

(8) Any additional comments on the application?

  No.

(9) Please summarise the action(s) you propose the Expert Committee take.

  Based on provided documentation and evidence we recommend the incorporation of early stage cervical cancer treatment options into the WHO Model List of Essential Medicines, and recommend specifically that cisplatin be added to the core Essential Medicines List.